GeneLancet Biosciences, Inc. is pioneering advancements in gene editing through its proprietary LgRNA technology, which facilitates precise gene editing using ultra-pure, high-quality ligated single molecule guide RNAs (LgRNA). This innovative approach enhances the activity of gene editing at challenging target sites, making it particularly effective for developing therapeutic solutions for a range of diseases, including rare monogenic conditions, cancer, and viral infections. The company’s platform is designed to address significant unmet medical needs by utilizing LgRNA-conjugates-directed CRISPR gene editing, which promises to improve the efficacy and safety of therapeutic interventions.

In addition to LgRNA technology, GeneLancet is advancing its non-immunogenic STAR Editor platform, which aims to cure genetic diseases with minimal collateral damage. This platform employs a four-step process to precisely edit DNA, allowing for the disruption and repair of diseased genes. The STAR Editor utilizes LgRNA as a gene editing template, ensuring high purity and specificity while minimizing immunogenic responses. Furthermore, the platform supports various delivery methods, including lipid nanoparticle (LNP) systems and non-immunogenic ribonucleoprotein (RNP) conjugates, enabling effective in vivo applications and enhancing the potential for targeted therapies.

United States

GeneLancet Biosciences is a gene editing company offering high-quality ligated single-molecule guide RNAs (LgRNA) and highly-reliable and cost-effective arrayed LgRNA libraries.

GeneLancet Biosciences, Inc.

Company Details